Visteon (VC) Q3 2025 earnings summary

Executive summary

• Q3 2025 sales were $917 million, down 6% year-over-year, mainly due to lower BMS sales and JLR production downtime.

• Adjusted EBITDA was $119 million (13% margin), with net income of $57 million and adjusted EPS of $2.15.

• Adjusted free cash flow was $110 million, supported by strong operational execution and favorable cash flow timing.

• 28 new products launched and $1.8 billion in new business secured in Q3; year-to-date new business wins reached $5.7 billion.

• Paid first quarterly dividend of $0.275 per share and resumed share repurchases, ending Q3 with $459 million in net cash.

Financial highlights

• Q3 2025 net sales were $917 million, down from $980 million in Q3 2024.

• Adjusted EBITDA margin expanded by 90 bps year-over-year to 13.0%.

• Adjusted net income for Q3 2025 was $60 million, with diluted EPS of $2.04 and adjusted EPS of $2.15.

• Adjusted free cash flow for the quarter was $110 million, with year-to-date adjusted FCF at $215 million.

• Gross margin for Q3 2025 was $131 million, with an adjusted gross margin of $136 million (14.8% of sales).

Outlook and guidance

• Full-year 2025 sales expected near $3.75 billion, below midpoint of prior guidance due to BMS and JLR headwinds.

• Adjusted EBITDA and free cash flow are tracking toward the high end of guidance ($475M–$505M and $195M–$225M, respectively).

• Q4 margins expected to remain in the mid-12% range, with modest sequential sales increase.

• CapEx for the year projected at $140 million, slightly below initial expectations.

• Guidance does not include potential impact from Nexperia supply disruptions.